Matrix metalloproteinase-3 (MMP-3)–mediated gene therapy for glaucoma
Science Advances · 21.04.2023 · 9 (16)
DOI: 10.1126/sciadv.adf6537 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, erschienen am 21.04.2023. Verfasst von Jeffrey O'Callaghan und 13 weiteren Autor:innen. Beteiligte Einrichtung: Smurfit Institute of Genetics, Trinity College Dublin, Dublin 2, Ireland. Hauptthemen laut MEDLINE: Intraocular Pressure, Glaucoma. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Approximately 80 million people globally are affected by glaucoma, with a projected increase to over 110 million by 2040. Substantial issues surrounding patient compliance remain with topical eye drops, and up to 10% of patients become treatment resistant, putting them at risk of permanent vision loss. The major risk factor for glaucoma is elevated intraocular pressure, which is regulated by the balance between the secretion of aqueous humor and the resistance to its flow across the conventional outflow pathway. Here, we show that adeno-associated virus 9 (AAV9)–mediated expression of matrix metalloproteinase-3 (MMP-3) can increase outflow in two murine models of glaucoma and in nonhuman primates. We show that long-term AAV9 transduction of the corneal endothelium in the nonhuman primate is safe and well tolerated. Last, MMP-3 increases outflow in donor human eyes. Collectively, our data suggest that glaucoma can be readily treated with gene therapy–based methods, paving the way for deployment in clinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Smurfit Institute of Genetics, Trinity College Dublin, Dublin 2, Ireland.
- Virscio Inc., New Haven, CT, USA.
- Department of Bioengineering, Imperial College London, London, UK.
- Institute of Functional and Clinical Anatomy, University of Erlangen-Nuremburg, Erlangen, Germany.
- Department of Ophthalmology, Antwerp University Hospital (UZA), Edegem, Belgium.
- Exhaura, 10 Earlsfort Terrace, Dublin 2, Ireland.
ORCID-Profile: Jeffrey O'Callaghan, Conor Delaney, Joseph van Batenburg-Sherwood, Martin Schicht, Sorcha Ni Dhubhghaill, Chris Stanley, Thomas Chalberg, Matthew S Lawrence, Matthew Campbell
Zitieren
APA
O'Callaghan, J., Delaney, C., O'Connor, M., van Batenburg-Sherwood, J., Schicht, M., Lütjen-Drecoll, E., Hudson, N., Ni Dhubhghaill, S., Humphries, P., Stanley, C., Keravala, A., Chalberg, T., Lawrence, M. S., & Campbell, M. (2023). Matrix metalloproteinase-3 (MMP-3)–mediated gene therapy for glaucoma. Science Advances, 9(16). https://doi.org/10.1126/sciadv.adf6537
Vancouver
O'Callaghan J, Delaney C, O'Connor M, van Batenburg-Sherwood J, Schicht M, Lütjen-Drecoll E, et al. Matrix metalloproteinase-3 (MMP-3)–mediated gene therapy for glaucoma. Science Advances. 2023;9(16). doi:10.1126/sciadv.adf6537
BibTeX
@article{OCallaghan2023,
author = {O'Callaghan, Jeffrey and Delaney, Conor and O'Connor, Merissa and van Batenburg-Sherwood, Joseph and Schicht, Martin and Lütjen-Drecoll, Elke and Hudson, Natalie and Ni Dhubhghaill, Sorcha and Humphries, Peter and Stanley, Chris and Keravala, Annahita and Chalberg, Thomas and Lawrence, Matthew S and Campbell, Matthew},
title = {Matrix metalloproteinase-3 (MMP-3)–mediated gene therapy for glaucoma},
journal = {Science Advances},
year = {2023},
volume = {9},
number = {16},
doi = {10.1126/sciadv.adf6537}
}
EUVIMED